by The global bronchial spasm market consists of various pharmaceutical drugs and natural remedies that are used to treat bronchospasms. Bronchospasm is a condition characterized by sudden tightening or constriction of the muscles in the walls of the bronchial tubes, which causes difficulty in breathing. Some common causes of bronchospasms include asthma, chronic obstructive pulmonary disease (COPD), bronchitis, and exposure to air pollutants or allergens. Pharmaceutical drugs utilized in treating bronchospasm include short-acting beta2-agonists such as albuterol, anticholinergic agents like ipratropium bromide, and corticosteroids. These drugs work by relaxing the muscles in the bronchial tubes and reducing inflammation and swelling of airways. However, there has been a growing demand for natural and herbal remedies due to the potential side effects of pharmaceutical medications.
The Global Bronchial Spasm Market is estimated to be valued at US$ 9.6 billion in 2024 and is expected to exhibit a CAGR of 6.1% over the forecast period 2024-2028.
Key Takeaways
Key players operating in the bronchial spasm market are Teva Pharmaceuticals, GlaxoSmithKline, Boehringer Ingelheim, Pfizer, and Sunovion Pharmaceuticals. These companies offer a wide range of pharmaceutical drugs for treating bronchospasms.
The growing prevalence of respiratory disorders like asthma and COPD worldwide has been a major factor driving the demand for bronchial spasm medications. According to some estimates, over 300 million people suffer from asthma globally.
Rising awareness about complementary and alternative therapies has also boosted the global expansion of the bronchial spasm market. Several emerging markets in Asia and Latin America are witnessing an uptick in sales of herbal remedies and supplements.
Market Key Trends
One of the key trends being witnessed in the bronchial spasm market is the increasing popularity of natural remedies and supplements. Consumers are showing more inclination towards herbal products made from ingredients like turmeric, ginger, garlic, and cannabis due to concerns over dependence on pharmaceutical medications. Cannabidiol (CBD) supplements in particular have gained significant traction as treatment for bronchospasm symptoms. Various studies have demonstrated CBD’s anti-inflammatory and bronchodilating properties, encouraging its use as an alternative remedy. This shift towards natural solutions is expected to remain a major driver of growth in the coming years.
Porter’s Analysis
Threat of new entrants: Low as it requires extensive R&D and clinical trials to develop drugs. Large capital is also required to enter the market.
Bargaining power of buyers: Moderate as there are many established players, but new products can increase customers’ bargaining power.
Bargaining power of suppliers: Low due to availability of raw material sources and suppliers globally.
Threat of new substitutes: Moderate threat from alternative treatment options and therapies.
Competitive rivalry: High among leading players to sustain or increase their market share through new product launches and marketing initiatives.
Geographical Regions
North America accounts for the largest share of the bronchial spasm market in terms of value due to rising incidence of respiratory diseases, increased healthcare spending and presence of leading drug manufacturers.
Asia Pacific is poised to grow at the fastest rate during the forecast period driven by expanding healthcare infrastructure, rising medical tourism, growing health awareness and increasing pollution levels in major countries such as India and China.
What Are The Key Data Covered In This Bronchial Spasm Market Report?
:- Market CAGR throughout the predicted period
:- Comprehensive information on the aspects that will drive the Bronchial Spasm ‘s growth between 2024 and 2031.
:- Accurate calculation of the size of the Bronchial Spasm and its contribution to the market, with emphasis on the parent market
:- Realistic forecasts of future trends and changes in consumer behaviour
:- Bronchial Spasm Industry Growth in North America, APAC, Europe, South America, the Middle East, and Africa
:- A complete examination of the market’s competitive landscape, as well as extensive information on vendors
:- Detailed examination of the factors that will impede the expansion of Bronchial Spasm vendors
Writer, has a strong foothold in the market research industry. She specializes in writing well-researched
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
About Author - Money Singh
Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc. LinkedIn Profile
